Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fadi Towfic

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
BMC Bioinformatics|May 12, 2012
Protein-RNA interface residue prediction using machine learning: an assessment of the state of the artRasna R Walia, Cornelia Caragea, Benjamin A Lewis, et al.
BMC Medical Genomics|December 19, 2021
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysMaría Ortiz-Estévez, Fadi Towfic, Erin Flynt, et al.
Blood|August 19, 2022
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMMNicholas Stong, María Ortiz-Estévez, Fadi Towfic, et al.
Plos One|January 15, 2014
Comparing the biological impact of glatiramer acetate with the biological impact of a genericFadi Towfic, Jason M Funt, Kevin D Fowler, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Genome-wide siRNA screen for mediators of NF-κB activationBenjamin E Gewurz, Fadi Towfic, Jessica C Mar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCLPatrick R Hagner, Hsiling Chiu, Vivek S Chopra, et al.
Genome Medicine|June 2, 2017
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosisColin J Ross, Fadi Towfic, Jyoti Shankar, et al.
Blood|October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaNaser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
Leukemia|November 14, 2019
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBNChad C Bjorklund, Jian Kang, Michael Amatangelo, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
BMC Bioinformatics|May 12, 2012
Protein-RNA interface residue prediction using machine learning: an assessment of the state of the artRasna R Walia, Cornelia Caragea, Benjamin A Lewis, et al.
BMC Medical Genomics|December 19, 2021
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysMaría Ortiz-Estévez, Fadi Towfic, Erin Flynt, et al.
Blood|August 19, 2022
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMMNicholas Stong, María Ortiz-Estévez, Fadi Towfic, et al.
Plos One|January 15, 2014
Comparing the biological impact of glatiramer acetate with the biological impact of a genericFadi Towfic, Jason M Funt, Kevin D Fowler, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Genome-wide siRNA screen for mediators of NF-κB activationBenjamin E Gewurz, Fadi Towfic, Jessica C Mar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCLPatrick R Hagner, Hsiling Chiu, Vivek S Chopra, et al.
Genome Medicine|June 2, 2017
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosisColin J Ross, Fadi Towfic, Jyoti Shankar, et al.
Blood|October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaNaser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
Leukemia|November 14, 2019
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBNChad C Bjorklund, Jian Kang, Michael Amatangelo, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Pageof 4